Parkinson's disease
Conditions
Interventions
Research and clinical validation of new treatment intervention methods for PD:Long-term home rehabilitation treatment:The subjects received routine medication treatment and underwent home-based rehabi
Research and clinical validation of new treatment intervention methods for PD:Mid-term home rehabilitation treatment:The subjects received routine medication treatment and underwent home-based rehabil
Research and clinical validation of new treatment intervention methods for PD:Short-term home rehabilitation treatment:The subjects received routine medication treatment and underwent home-based rehab
Establishment of Parkinson's Disease (PD) Behavioral Markers: PD group:NA
Establishment of Parkinson's Disease (PD) Behavioral Markers:Healthy control group:NA
Construction of PD Clinical Quantitative Evaluation Model and Early Intelligent Diagnosis Model:NA
Sponsors
Beijing Hospital
Eligibility
Sex/Gender
All
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: Part 1 (Establishment of Parkinson's Disease (PD) Behavioral Markers) and Part 2 (Construction of PD Clinical Quantitative Evaluation Model and Early Intelligent Diagnosis Model): 1. PD subjects enrollment criteria (1) Age 50-80 years old (2) Patients with clinically confirmed or probable Parkinson's disease who meet the 2016 Chinese Parkinson's disease diagnostic criteria (3) H-Y stage <= 2.5 (in line with early-onset PD) 2. Health control enrollment criteria (1) Age 50-80 years old and voluntarily sign the informed consent form Part 3 (Research and clinical validation of new treatment intervention methods for PD): 1. PD subjects enrollment criteria (1) Age 50-80 years old (2) Patients with clinically confirmed or probable Parkinson's disease who meet the 2016 Chinese Parkinson's disease diagnostic criteria (3) H-Y stage <= 2.5 (in line with early-onset PD)
Exclusion criteria
Exclusion criteria: Part 1 (Establishment of Parkinson's Disease (PD) Behavioral Markers) and Part 2 (Construction of PD Clinical Quantitative Evaluation Model and Early Intelligent Diagnosis Model): 1. PD subject exclusion criteria (1) Patients diagnosed with Parkinson's syndromes other than primary Parkinson's disease, or patients with unclear diagnosis (2) Previous history of stroke or intracranial mass occupancy (3) Patients with previous ophthalmic diseases that affect eye movement (4) Any neurological disease or musculoskeletal injury that interferes with gait or balance other than Parkinson's motor symptoms (such as fractures, sequelae of stroke, etc.) (5) Suffering from serious organic diseases, such as advanced tumors, etc., with a life expectancy of no more than 2 years (6) Patients with mental illness or other reasons who cannot cooperate (7) Undergoing other clinical trials at the same time 2. Healthy control exclusion criteria (1) Patients with previous stroke, intracranial mass occupancy and neurodegenerative diseases (2) Patients with previous ophthalmic diseases that affect eye movement (3) Previous nervous system or musculoskeletal injuries that interfere with gait or balance (such as fractures, sequelae of stroke, etc.) (4) Suffering from serious organic diseases, such as advanced tumors, etc., with a life expectancy of no more than 2 years (5) Patients with mental illness or other reasons cannot cooperate (6) Undergoing other clinical trials at the same time Part 3 (Research and clinical validation of new treatment intervention methods for PD): 1. PD subject exclusion criteria (1) Patients diagnosed with Parkinson's syndromes other than primary Parkinson's disease, or patients with unclear diagnosis (2) Previous history of stroke or intracranial mass occupancy (3) Patients with previous ophthalmic diseases that affect eye movement (4) Any neurological disease or musculoskeletal injury that interferes with gait or balance other than Parkinson's motor symptoms (such as fractures, sequelae of stroke, etc.) (5) Suffering from serious organic diseases, such as advanced tumors, etc., with a life expectancy of no more than 2 years (6) Patients with mental illness or other reasons who cannot cooperate (7) Undergoing other clinical trials at the same time (8) Unable to accept the required treatment and follow-up due to geographical reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MDS-UPDRS III score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Sum score of MDS-UPDRS part I+II+III;ReadyGo motion features;Oculomotor parameters by EyeKnow;Mental State ;Cognitive;Hamilton Anxiety Scale Score;Hamilton Depression Scale Score;Epworth sleepiness scale score;The Parkinson's Disease Sleep Scale-2 Score;Water Swallow ;Swallowing Disturbance Questionnaire Score;Activity of Daily Life;Levodopa equivalent dosage; | — |
Countries
China
Contacts
Public ContactWen Su
Beijing Hospital
Outcome results
None listed